Hepatitis Therapeutics Market Size, Share & Trends Analysis Report By Disease (Hepatitis A, Hepatitis B, Hepatitis C), By Distribution Channel (Hospital Pharmacies), By Region, And Segment Forecasts, 2024 - 2030

Hepatitis Therapeutics Market Size & Trends

The global hepatitis therapeutics market size was valued at USD 16.27 billion in 2023 and is projected to grow at a CAGR of 3.7% from 2024 to 2030. Rising hepatitis cases, autoimmune disorders, and global healthcare spending are fueling the hepatitis treatment market, with growing awareness and new technologies further accelerating its growth. For instance, according to the WHO, an estimated 304 million people globally were living with chronic hepatitis B or C in 2022, with these viruses claiming 3,500 lives each day.

The increasing prevalence of autoimmune diseases is contributing to the growth of the hepatitis therapeutics market. As autoimmune conditions become more common, they can lead to liver complications such as autoimmune hepatitis, thereby expanding the demand for treatments aimed at managing and mitigating these conditions. According to a study published by THE LANCET, a UK study (22 million people) found that autoimmune diseases affect 10% of the population. Researchers examined electronic health records to understand trends, who is most affected, and how these diseases co-exist. The study also identified variations based on socioeconomic status, season, and region, which may explain why autoimmune diseases develop.

Rising global healthcare spending, particularly in hepatitis-endemic regions, fuels the hepatitis treatment market by increasing treatment development and implementation resources. For instance, U.S. healthcare spending reached USD 4.5 trillion in 2022, with hospitals receiving the largest share (24.34%) followed by physicians (13.6%) and prescription drugs (13.58%).

Disease Insights

The hepatitis C segment dominated the market share in 83.6% in 2023. More effective and tolerable anti-HCV drugs are fueling growth in the hepatitis treatment market. According to THE LANCET Gastroenterology & Hepatology, direct-acting antivirals (DAAs) achieved high response rates (>95%) in treating hepatitis C virus (HCV) infection and simplified its management, enabling non-specialists to oversee patients even without advanced liver disease. These medications represent a significant advancement, offering shorter treatment durations and fewer side effects compared to older therapies.

The Hepatitis B segment is expected to grow at the fastest CAGR over the forecast period. More people with chronic hepatitis B are driving the market for better treatments, tests, and awareness programs. For instance, chronic hepatitis B is a serious global issue with over 254 million infected worldwide, causing 1.1 million deaths annually from liver complications.

Distribution Channel Insights

The hospital pharmacies segment dominated the market and accounted for 53.2% in 2023. Increased awareness, better diagnosis, and rising infection rates are fueling demand for hepatitis B and C treatments. According to the hepb.org (Hepatitis B Foundation), hepatitis B infected 2 billion people globally, with around 1.5 million infections are being annually and nearly 300 million chronic cases. Only about 10% of the infected are diagnosed.

The drug stores and retail pharmacies segment is expected to grow significantly over the forecast period. The hepatitis therapeutics market for drug stores and retail pharmacies is driven by the rising prevalence of hepatitis B and C, increased public awareness and education, medication advancements, and improved healthcare access and insurance coverage, which makes treatments more affordable and accessible.

Regional Insights & Trends

North America hepatitis therapeutics market dominated in 2023, with a revenue share of 41.3%. Due to high demand, higher affordability of patient population, and awareness among the region, which played a vital role in developing the market. In addition, the presence of well-developed infrastructure and pharmaceutical organizations also played a vital role. According to the UC (University of California) Regents, enhanced premium subsidies for marketplace plans are extended through 2025, with North Carolina's Medicaid expansion potentially encouraging other states to follow and some states using their funds to cover undocumented persons.

Medicare is expected to start negotiating drug prices in 2026, which may affect private pricing. Quality improvements focus on prevention, increased use of electronic health records and telehealth, and growing consumer use of comparative performance data alongside various federal and private initiatives to enhance care quality, including pay-for-performance programs.

U.S. Hepatitis Therapeutics Market Trends

The U.S. dominated the North American hepatitis therapeutics market with 88.7% of the revenue share in 2023. Widespread drug availability, public awareness, and major pharma players are driving the U.S. hepatitis B drug market growth. For instance, in July 2024, the FDA's approval of Cepheid's Xpert HCV test offers rapid Hepatitis C diagnosis in doctor offices and clinics using a finger prick, potentially improving access to testing and treatment.

Europe Hepatitis Therapeutics Market Trends

Europe's hepatitis therapeutics market is expected to grow significantly over the forecast period due to the rising hepatitis cases, strong healthcare infrastructure, and easy testing access are fueling Europe's hepatitis therapeutics market growth. For instance, in England, an estimated 0.45% (around 206,000) live with chronic HBV, mostly migrants infected abroad before coming to the UK.

Germany had a significant contribution in growing hepatitis therapeutics market in Europe as they hold large population as compared to the other countries of Europe and the initiatives taken by the governments and the awareness among people also played a very major role. According to the Deutsches Zentrum für Infektionsforschung (DZIF), researchers at DZIF are developing a two-step approach to curing Hepatitis B. They aim to lower the number of viruses in the body and boost the immune system's ability to fight them. To achieve this, they're testing antiviral drugs and new immune therapies, such as a special vaccine and T-cell treatments.

Asia Pacific Hepatitis Therapeutics Market Trends

The Asia Pacific hepatitis therapeutics market is expected to grow at a compounded annual growth rate of 6.6% during the forecast period of 2024 to 2030. The presence of a high disease burden and rising awareness about hepatitis are positively impacting the market in the region. For instance, the Asia Pacific bears the highest hepatitis burden, with the world's largest number of hepatitis C cases at 8.8 million in Pakistan. Evidence indicates that healthcare-related exposure, such as inadequate sterilization of medical equipment, primarily drives disease transmission in this region.

Developing nations such as India and China are investing in healthcare infrastructure to improve access to quality care. For instance, China's healthcare market, valued at USD 1.5 trillion in 2021, was expected to surge to USD 2.4 trillion by 2030, fueled by the government's "Healthy China 2030" initiative.

Key Hepatitis Therapeutics Company Insights

Some of the key companies operating in the hepatitis therapeutics market include Teva Pharmaceutical Industries Ltd., Bristol-Myers Squibb Company, F. Hoffmann-La Roche Ltd, Zydus Group, GSK plc, AbbVie Inc., Gilead Sciences, Inc., Merck & Co., Inc., Lupin, and Cipla. Vendors in the market are focusing on increasing customer base to gain a competitive edge in the industry. Therefore, key players are taking several strategic initiatives, such as mergers and acquisitions, and partnerships with other major companies.

Recent Developments

• In February 2024, the U.S. Food and Drug Administration (FDA) prioritized GSK plc's bepirovirsen for development as a treatment for chronic hepatitis B. This drug is undergoing phase 3 clinical trials to confirm its effectiveness.

• In October 2023, Rostec was expected to launch Antigen-Neo, Russia's first intravenous specific immunoglobulin for hepatitis B prevention in children and adults. It was approved for preventing hepatitis B and is also effective for cases transmitted from hepatitis B surface antigen-positive pregnant women.

Hepatitis Therapeutics Market Report Scope

Global Hepatitis Therapeutics Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2018 to 2030. For this study, Grand View Research has segmented the global hepatitis therapeutics market report based on disease, distribution channel, and region. 

• Disease Outlook (Revenue, USD Million, 2018 - 2030)

  • Hepatitis A

  • Hepatitis B

  • Hepatitis C

  • Others

• Distribution Channel Outlook (Revenue, USD Million, 2018 - 2030)

  • Hospital Pharmacies

  • Drug Stores and Retail Pharmacies

  • Others

• Regional Outlook (Revenue, USD Million, 2018 - 2030)

  • North America

    • U.S.

    • Canada

    • Mexico

  • Europe

    • UK

    • Germany

    • France

    • Italy

    • Spain

    • Denmark

    • Sweden

    • Norway

  • Asia Pacific

    • Japan

    • China

    • India

    • Australia

    • Thailand

    • South Korea

  • Latin America

    • Brazil

    • Argentina

  • Middle East and Africa (MEA)

    • South Africa

    • Saudi Arabia

    • UAE

    • Kuwait